LC
AKYA

Lindbrook Capital’s Akoya BioSciences AKYA Stock Holding History

Lindbrook Capital’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-217
Closed -$1.6K – 2687
2023
Q2 		$1.6K Buy
+217
New +$1.45K ﹤0.01% 2234

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Lindbrook Capital's AKYA Position: Q3 2023 in Review

Lindbrook Capital sold out of Akoya BioSciences (AKYA) in Q3 2023, closing a stake of 217 shares — an estimated $1.6K sold.

Lindbrook Capital first reported a position in AKYA in Q2 2023 and held it in 1 quarter. The position peaked at $1.6K in Q2 2023. 62 funds tracked by Wall St. Rank hold AKYA as of Q3 2023.

  • Lindbrook Capital reported no remaining Akoya BioSciences position as of Q3 2023 after selling out during the quarter.
  • Lindbrook Capital sold 217 Akoya BioSciences shares in Q3 2023, an estimated $1.6K.
  • Lindbrook Capital first reported a position in Akoya BioSciences in Q2 2023 and held it in 1 quarter.
  • Lindbrook Capital's Akoya BioSciences position peaked at $1.6K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2023.

Based on Lindbrook Capital's 13F filing for Q3 2023, filed 25 Oct 2023.